Anti-Coagulant Treatment For Atrial Fibrillation Does Not Worsen Outcomes for Patients With Kidney Disease
Chicago – Although some research has suggested that the use of the anticoagulant warfarin for atrial fibrillation among patients with chronic kidney disease would increase the risk of death or stroke, a study that included more than 24,000 patients found a lower l-year risk of the combined outcomes of death, heart attack or stroke without a higher risk of bleeding, according to a study in the March 5 issue of JAMA.
Juan Jesus Carrero, Ph.D., of the Karolinska Institutet, Stockholm, and colleagues examined outcomes associated with warfarin treatment in relation to kidney function among patients with established cardiovascular disease and atrial fibrillation. Using data from a Swedish registry, the study included survivors of a heart attack with atrial fibrillation and known measures of serum creatinine (n = 24,317; a substance used to measure kidney function), including 21.8 percent who were prescribed warfarin at discharge.
ICU Patients with acute kidney injury show high mortality rates and elevated urinary protein levels at 4-year follow up
In 4 years of follow up of 1464 participants in the randomized controlled trial Randomised Evaluation of Normal vs. Augmented Levels of RRT (RENAL) study, Martin Gallagher (The George Institute for Global Health, Sydney, Australia) and colleagues found that patients with acute kidney injury (AKI) in an intensive care unit (ICU) who require renal replacement therapy (RRT; hemodialysis combined with hemofiltration) do not benefit from higher intensity RRT. At a median of 43.9 months follow up, mortality (63% in the low intensity and 63% in the high intensity group), as well as quality of life among those who survived, were the same in both groups. Albuminuria (elevated protein levels in urine, signifying persistent kidney injury) was common among survivors and with equal rates in both groups (40% in the low intensity and 44% in the high intensity group). Read more…
Scientists have developed “smart stethoscope” that could help to monitor the progress and effectiveness of the kidney stone therapy.
This research has been done by researchers from the University of Southampton and their collaborators, and has been published online in the journal Proceedings of the Royal Society A.
One of the favored procedures for the removal of kidney stones is lithotripsy. It is the medical fragmentation of a stone in the urinary system or gallbladder with the help of ultrasound shock waves, so that the pieces of stone could easily pass out of the body through urine or dissolved by drug. However, the difficulty occurs in the process of checking the stones in the body i.e. whether the stones broke and procedure has been completed or not.
With the help of this new “smart stethoscope” physicians could check whether the treatment for kidney stones work or not. This stethoscope is placed on the patient’s skin after shock wave treatment for kidney stones and it listens to the echoes reverberating around the body after the shock wave hits the stone. Read more…
Researchers have found that kidney transplant could result in increased chances of cancer.
This study has been conducted by Italian researchers and published online in the European Journal of Cancer.
Researchers in this study worked on 7,217 kidney transplant recipients, in whom the transplantation was done in the years between 1997 and 2007, and followed up until 2009.
Researchers found that 395 patients were diagnosed with de novo cancers including Kaposi’s sarcoma (KS), post-transplant lymphoproliferative disorders (PTLD), particularly non-Hodgkin’ lymphoma (NHL), lung, kidney and prostate as the most common types.
If we consider the geographical distribution, researchers have reported that the kidney transplant recipients from Southern Italy have decreased chances of kidney cancer and solid tumors while they are at increased risk of Kaposi’s sarcoma as compared to the recipients born in Northern Italy. Read more…
Researchers have found that black patients of kidney problem i.e. end stage renal disease (ESRD) had a 59% reduced rate of kidney transplant as compared to white patients in a southeastern Emory Transplant Center.
This research has been conducted by Rachel Patzer, PhD, of Emory University in Atlanta, and colleagues, and published online in January 10 issue of the American Journal of Transplantation.
Researchers worked on 2291 patients at Emory transplant center as well as those from the United States Renal Data System and the United Network for Organ Sharing, from 2005 to 2007 followed through May 2010, and found “racial disparities” in access to transplant evaluation, referral, wait-listing and eventual transplant. “Of 2291 patients, 64.9% were black, the mean age was 49.4 years and 33.6% lived in poor neighborhoods.” Among them 57.3% were male and 16.1% were without any health insurance coverage. Read more…